ImmunoPrecise Antibodies Ltd. Announces AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation ImmunoPrecise Antibodies Ltd. $(IPA)$ has announced new in vitro results for its AI-designed GLP-1 receptor agonist peptides, which have shown comparable or superior receptor activation to Semaglutide, a leading GLP-1 therapy. The analysis, conducted by an independent third party, highlights the potential of AI in generating functionally validated peptide drugs. The company is exploring two preclinical paths for its GLP-1 candidates: injectable delivery studies and non-invasive delivery strategies, such as transdermal patches and nucleic acid-based delivery systems. These developments align with ImmunoPrecise's goals of enhancing therapeutic durability, patient compliance, and ease of administration. The results, demonstrating the efficacy of the HYFT-driven design approach, have already been presented, marking a significant step in AI-powered drug discovery with applications extending to other therapeutic areas.